Aarti Pharmalabs Limited · NSE:AARTIPHARM

Aarti Pharmalabs — Shareholder Meeting (September 2026)

11 slides from Aarti Pharmalabs's shareholder meeting presentation, Sep 22, 2026

  1. Slide 1: Letter to stock exchanges: Investor Presentation

    September 22, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai - 400 001 G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 SCRIP CODE:

  2. Slide 2: Aarti Pharmalabs Limited 7th Annual General Meeting

    Aarti Pharmalabs Aarti PharmalabsLimited Limited Annual General 7th Annual MeetingMeeting General September 2026 22nd September 2026

  3. Slide 3: Corporate Scale & Operational Reach

    Corporate Scale & Operational Reach 25+ Years of Pharmaceutical Excellence 220+ Products 500+ Global Clients State-of-the-art 3 R&D facilities 63 Patents Filed 50+ Export Countries Manufacturing 7 Units 60 US DMF 2,400+ Employees 3 USFDA Units 44 CEP Global 15-20% Market Share 0.32x Net Debt/Equity

  4. Slide 4: Company Profile & Competitive Edge

    Company Profile & Competitive Edge • Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with STANDALONE REVENUE (INR Cr) group turnover of INR 150+ bn (FY26) & EBITDA MARGINS (%) 1,798 1,771 • Globally recognized manufacturer of generic API, Xanthine deriv

  5. Slide 5: Growth Journey & Value Creation

    Growth Journey & Value Creation 2026 • Inaugurated Tarapur(Unit 5), adding 3,600 TPA to reach a total capacity of 9,600 TPA 2024 • Started 21 MW solar power project at Akola, Maharashtra • Expansion of semi-commercial production block at Vapi 13 2022 12 • Expanded block at CSD Vapi & API In Tarapur

  6. Slide 6: Standalone Multi-year Profitability Metrics

    Standalone Multi-year Profitability Metrics Operational Revenue(INR Cr) EBITDA & Margin(INR Cr / %) PAT (INR Cr) FY23 1,511 FY23 308 FY23 172 20.4% FY24 1,502 FY24 346 FY24 201 23% FY25 1,771 FY25 427 FY25 257 24% FY26 1,798 FY26 406 FY26 176 22.6% 5 Aarti Pharmalabs Limited

  7. Slide 7: Standalone Profit & Loss Statement

    Standalone Profit & Loss Statement PARTICULARS (INR Mn) FY26 FY25 Y-O-Y Operational Revenue 17,976 17,714 1.5% Operating Expenses 13,915 13,449 3.5% EBITDA 4,061 4,265 (4.8)% EBITDA Margin (%) 22.59% 24.08% (149) Bps Depreciation and Amortisation 1,043 791 31.9% Finance costs 469 256 83.2% Foreign Ex

  8. Slide 8: Consolidated Profit & Loss Statement

    Consolidated Profit & Loss Statement PARTICULARS (INR Mn) FY26* FY25 Y-O-Y Operational Revenue 18,194 21,151 (14.0)% Operating Expenses 14,170 16,507 (14.2)% EBITDA 4,024 4,644 (13.4)% EBITDA Margin (%) 22.12% 21.96% 16 Bps Depreciation and Amortisation 1,043 869 20.0% Finance costs 469 269 74.3% For

  9. Slide 9: Recent Investments

    Recent Investments Greenfield Capex – Atali Project (Gujarat) Brownfield Capex – Tarapur (Maharashtra) Estimated Investment INR 400 crores Estimated Investment INR 210 crores Capacity ~450 KL (Block 1) Proposed Capacity 9,000 MTPA Land Available 80 acres Current Utilization 6,000 MTPA Timeline ~80%

  10. Slide 10: Future Outlook

    Future Outlook FY26 CAPEX reached ~ INR 400 cr; FY27 outlook expected at similar levels Targeting 15-18% Initiating R&D investment in FY27 towards TIDES (Peptides Revenue & EBITDA CAGR & Oligonucleotides) to expand portfolio capabilities. Over the Next 3-4 Years Announced capex for Atali Block 2 for

  11. Slide 11: Thank You

    THANK YOU AARTI PHARMALABS LIMITED

Aarti Pharmalabs — Shareholder Meeting (September 2026) on 6ix